Abstract: The present invention belongs to the area of pharmaceutical and cosmetic compositions and refers to compounds, novel mixtures and preparations comprising certain compound(s) of formula (I) which show anti-inflammatory properties.

Abstract: The present invention belongs to the area of pharmaceutical and cosmetic compositions and refers to compounds, novel mixtures and preparations comprising certain compound(s) of formula (I) which show anti-inflammatory properties.

Abstract: The present invention primarily relates to a combination agent for reducing appetite and/or for providing a feeling of satiety and/or for reducing energy intake and/or for reducing body weight. In addition, the present invention relates to a medical use of the combination agent, in particular for the treatment of overweight and obesity and for the prevention of cardiovascular disease, stroke, diabetes, and joint damage and wear of the spine, and to a non-therapeutic use of the combination agent. In particular, the focus of the present invention is on the use of the combination agent to provide a feeling of satiety and/or to reduce energy intake and/or to reduce body weight. Finally, the present invention relates to the use of the combination agent for the preparation of an orally consumable preparation or food ingredient and an orally consumable preparation or food ingredient prepared therefrom.

Abstract: The present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group. In particular, the present invention refers to a composition comprising guaifenesin and one or more flavour compound(s) containing an isovanillyl group, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of guaifenesin and one or more flavour compounds containing an isovanillyl group for the preparation of a pharmaceutical composition. Finally, the present invention relates to the use of one or more flavour compound(s) containing an isovanillyl group for masking or inhibiting the bitter taste of guaifenesin or of guaifenesin comprising compositions.

Abstract: Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents.

Abstract: The present invention refers to a composition comprising eriodictyol and guaifenesin. In particular, the present invention refers to a composition comprising eriodictyol and guaifenesin, said composition being for medical use, in particular for use in the prevention and treatment of respiratory diseases. Moreover, the present invention relates to the use of eriodictyol and guaifenesin for the preparation of a pharmaceutical composition. Finally, the present invention relates to the use of eriodictyol for masking or inhibiting the bitter taste of guaifenesin or guaifenesin comprising compositions.

Abstract: The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).

Abstract: The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of homoeriodictyol (1), eriodictyol (2), hesperetin (3) and sterubin (4), for use in the treatment of an ailment which can be alleviated or prevented by influencing the serotonin level and the concentration of free fatty acids in the blood.

Abstract: Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents.

Abstract: The present invention particularly relates to new uses of compounds of formula (I) (as described herein) for inhibiting or reducing the absorption of free fatty acids in the small intestine, as well as a new compound of formula (I) as such, aroma compositions and new compositions comprising such a compound of formula (I). Further aspects of the present invention result from the patent claims and the subsequent description including the examples.

Abstract: The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).

Abstract: Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents.

Abstract: The invention relates to compounds of formula (I) or the salts thereof, said compounds of formula (I) being selected from among the group consisting of homoeriodictyol (1), eriodictyol (2), hesperetin (3) and sterubin (4), for use in the treatment of an ailment which can be alleviated or prevented by influencing the serotonin level and the concentration of free fatty acids in the blood.

Abstract: Suggested are new compositions for oral ingestion, comprising at least one active agent from the group of alkamides. The compositions which are orally ingested reduce the uptake of free fatty acids in the adipocytes and at the same time stimulate the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. In doing so, the new compositions are thus perfectly suitable to counteract any undesired gain of weight.

Abstract: Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents.

Abstract: The present invention is directed to a method for the identification of bitter tasting compounds and bitter taste modulating compounds, in particular bitter taste masking compounds (bitter antagonists) and bitter taste enhancing compounds (bitter agonists) by monitoring the change in the intracellular pH value and/or proton secretion.

Abstract: What are proposed are primarily aromatic alkenoic acid derivatives of the formula I for use in a therapeutic method as (a) means for reducing appetite and/or (b) means for causing a feeling of satiation and/or as (c) means for reducing energy intake and/or as (d) mood enhancers, and the non-therapeutic use of the aromatic alkenoic acid derivatives of formula I as (a) means for reducing appetite and/or (b) means for causing a feeling of satiation and/or as (c) means for reducing energy intake and/or as (d) mood enhancers.

Abstract: The invention provides a method of step-wise synthesizing copies of polymers of potentially different units on at least two solid carrier surfaces simultaneously in a preselected pattern, comprising providing a layered synthesis arrangement comprising a transparent first solid carrier and a second solid carrier, wherein said first and second carrier each contain an active surface to which polymer units can be applied dependent on reactions of photosensitive moieties, projecting light in a preselected pattern onto the first and second carrier surface, wherein the light passes through the transparent first solid carrier, whereby photons react with photosensitive moieties thereby activating the first surface, said pass-through light further projects onto the second carrier surface, whereby photons react with photosensitive moieties thereby activating the second surface, applying a fluid comprising a polymer unit to the first and second active surfaces and binding the polymer unit to the exposed sites of said pat

Abstract: Suggested are new compositions for oral ingestion, comprising at least one active agent from the group of alkamides. The compositions which are orally ingested reduce the uptake of free fatty acids in the adipocytes and at the same time stimulate the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. In doing so, the new compositions are thus perfectly suitable to counteract any undesired gain of weight.

Abstract: Suggested is a compound of the formula (X) or any salt of a compound of the formula (X) or any mixture containing or consisting of two or more different compounds of the formula (X), two or more different salts of compounds of the formula (X) or one or more different compounds of the formula (X) and one or more different salts of compounds of the formula (X), wherein for R1, R2 and R3 independently of one another in every compound of the formula (X) the following applies: R1 means hydrogen or methyl, R2 means an organic residue with 5 carbon atoms and one oxygen atom or none and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, or R1 and R2 together with the carbon atoms in positions 4 and 5 and the oxygen atom bound to the carbon atom in position 4 form a ring and comprise 5 carbon atoms and one oxygen atom or none, and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, for use in a method for the prophylaxis and/or treatment of inflammation.